Bladder Cancer Study Decision Tree
Explore Bladder Cancer Studies
CG Oncology CRETO-EAP
- An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Upper Tract
UROGEN (Jelmyto)
- A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
NMIBC – Low Grade
IR-NMIBC
TYRA 300
- A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
NMIBC – High Grade CIS BCG Naïve
Surge (STM-416-01)
- A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
Reoccurrence of NMIBC – High Grade After 1 Induction of BCG
Reoccurrence of NMIBC – High Grade Ta/T1 after adequate BCG
Core-008
- A Phase 2, Multi-Cohort, Open-Label Study of Creostimogene Grenadenorepvec in High-Risk NMIBC
Reoccurrence of NMIBC High Grade CIS +/- Papillary Tumors after adequate BCG